{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:27:36Z","timestamp":1789158456541,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.03.008","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:39:45Z","timestamp":1710607185000},"page":"653-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"Timothy","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhubin","family":"Gahvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0002","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2012-11-466011","article-title":"MGUS prevalence in an ethnically Chinese population in Hong Kong","volume":"121","author":"Wu","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clml.2013.12.010","article-title":"Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from Nagasaki atomic bomb survivors","volume":"14","author":"Iwanaga","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2024.03.008_bib0004","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(87)90375-5","article-title":"Evaluation of monoclonal gammopathies in the \"well\" elderly","volume":"82","author":"Crawford","year":"1987","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.03.008_bib0006","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2024.03.008_bib0007","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0008","doi-asserted-by":"crossref","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.clml.2024.03.008_bib0009","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamaoncol.2015.2938","article-title":"Agent orange exposure and monoclonal gammopathy of undetermined significance: an operation ranch hand veteran cohort study","volume":"1","author":"Landgren","year":"2015","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.clml.2024.03.008_bib0010","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0011","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaoncol.2018.0509","article-title":"Multiple myeloma and its precursor disease among firefighters exposed to the world trade center disaster","volume":"4","author":"Landgren","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.008_bib0012","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1182\/blood-2023-182169","article-title":"Increased risk of monoclonal gammopathy of undetermined significance in US military service members: a case-control study of 1,068 service members deployed to either Europe or Iraq, with or without reported burn pit and toxic smoke exposure","volume":"142","author":"Kazandjian","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.03.008_bib0013","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(09)70234-7","article-title":"Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case\u2013control study","volume":"10","author":"Grass","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.03.008_bib0014","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ijc.28731","article-title":"Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS\/MM","volume":"135","author":"Zwick","year":"2014","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.clml.2024.03.008_bib0015","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ng.2733","article-title":"Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nature Genet"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/bloodadvances.2019000491","article-title":"A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry","volume":"4","author":"Du","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0017","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1182\/bloodadvances.2020001435","article-title":"Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance","volume":"4","author":"Clay-Gilmour","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa0708704","article-title":"Familial Myeloma","volume":"359","author":"Lynch","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0019","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41375-018-0246-2","article-title":"Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics","volume":"33","author":"Clay-Gilmour","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.clml.2024.03.008_bib0020","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/blood-2011-11-387324","article-title":"Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics","volume":"119","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10552-015-0685-2","article-title":"Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features","volume":"27","author":"VanValkenburg","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"22","key":"10.1016\/j.clml.2024.03.008_bib0022","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2024.03.008_bib0023","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.03.008_bib0024","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2021-152333","article-title":"Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial. First results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study","volume":"138","author":"Kristinsson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.03.008_bib0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2023-186397","article-title":"The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the istopmm study","volume":"142","author":"R\u00f6gnvaldsson","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0026","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0027","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9727","key":"10.1016\/j.clml.2024.03.008_bib0028","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-020-01771-3","article-title":"The renal range of the \u03ba\/\u03bb sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease","volume":"21","author":"Molina-And\u00fajar","year":"2020","journal-title":"BMC Nephrol"},{"issue":"9","key":"10.1016\/j.clml.2024.03.008_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"Suppl_1","key":"10.1016\/j.clml.2024.03.008_bib0031","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2023-188547","article-title":"Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the istopmm study","volume":"142","author":"Long","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.03.008_bib0032","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0033","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.25441","article-title":"Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group","volume":"94","author":"Bustoros","year":"2019","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.008_bib0034","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2022-170166","article-title":"Predicting the need for upfront bone marrow sampling in individuals with MGUS: derivation of a multivariable prediction model using the prospective population-based istopmm cohort","volume":"140","author":"Eythorsson","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0035","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0036","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3109\/10428194.2010.525725","article-title":"Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"51","author":"Mailankody","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0037","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.03.008_bib0039","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.03.008_bib0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/ejh.12172","article-title":"Monoclonal gammopathy of undetermined significance: a new proposal of workup","volume":"91","author":"Mangiacavalli","year":"2013","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0041","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00256-008-0607-4","article-title":"Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)","volume":"38","author":"Gleeson","year":"2009","journal-title":"Skeletal Radiol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0042","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0043","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.ejrad.2013.08.036","article-title":"Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM)","volume":"82","author":"Ippolito","year":"2013","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0044","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/cancers12020486","article-title":"Imaging of monoclonal gammapathy of undetermined significance and smoldering multiple myeloma","volume":"12","author":"Jamet","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0046","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0048","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","article-title":"Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis","volume":"36","author":"Veronese","year":"2018","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0049","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER\u2013Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0050","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0051","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3816\/CLM.2009.n.002","article-title":"IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstr\u00f6m's macroglobulinemia","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"22","key":"10.1016\/j.clml.2024.03.008_bib0052","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood.V128.22.843.843","article-title":"Estimating the risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies in the United States: determining demographic differences using a national dataset","volume":"128","author":"Go","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0053","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0054","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.clml.2024.03.008_bib0055","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0056","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.03.008_bib0057","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0058","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.03.008_bib0059","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.03.008_bib0060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0061","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2024.03.008_bib0062","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.03.008_bib0063","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0064","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.03.008_bib0066","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","article-title":"Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria","volume":"37","author":"Miguel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2024.03.008_bib0067","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.03.008_bib0068","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"34","key":"10.1016\/j.clml.2024.03.008_bib0069","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.008_bib0070","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.clml.2024.03.008_bib0071","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0072","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0073","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0074","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0075","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fernandez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.03.008_bib0076","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0077","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2024.03.008_bib0078","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-021-00569-2","article-title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0079","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: a study of 406 patients","volume":"14","author":"Abdallah","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0081","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"23","key":"10.1016\/j.clml.2024.03.008_bib0082","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.03.008_bib0083","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.clml.2024.03.008_bib0084","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.03.008_bib0086","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0087","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0088","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1139662","article-title":"Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro","volume":"5","author":"Kramer","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.clml.2024.03.008_bib0089","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2024.03.008_bib0090","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0091","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry Part A"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0092","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.clml.2024.03.008_bib0093","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.03.008_bib0094","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.clml.2024.03.008_bib0095","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.03.008_bib0096","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood-2023-181765","article-title":"Efficacy and Safety of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM): final analysis of the phase 2 Centaurus study","volume":"142","author":"Landgren","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.03.008_bib0097","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.03.008_bib0098","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.03.008_bib0099","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0100","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.03.008_bib0101","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2019-125204","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed By HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.008_bib0102","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2022-159606","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): post-hoc analysis of sustained undetectable measurable residual disease (MRD)","volume":"140","author":"Mateos","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.03.008_bib0103","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple Myeloma-Results of the ascent trial","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.03.008_bib0104","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.03.008_bib0105","first-page":"1","article-title":"The role of early intervention in high-risk smoldering myeloma","volume":"40","author":"Joseph","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2024.03.008_bib0106","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2024.03.008_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102272","article-title":"Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey","volume":"65","author":"Mohyuddin","year":"2023","journal-title":"Eclinicalmedicine"},{"issue":"6","key":"10.1016\/j.clml.2024.03.008_bib0108","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clml.2024.03.008_bib0109","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.03.008_bib0110","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2024.03.008_bib0111","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.03.008_bib0112","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/blood-2019-128519","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"134","author":"Bustoros","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.03.008_bib0113","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:10:51Z","timestamp":1729696251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2152265024001150"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}